ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at
Open original source